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Acute myeloid leukemia (AML) is one of the deadly cancers. Chemotherapy is the first-line
treatment and the only curative intervention is stem cell transplantation which are intolerable
for aged and comorbid patients. Therefore, finding complementary treatment is still an active
research area. For this, empirical knowledge driven search for therapeutic agents have
been carried out by long and arduous wet lab processes. Nonetheless, currently there is an
accumulated bioinformatics data about natural products that enabled the use of efficient and
cost effective in silico methods to find drug candidates. In this work, therefore, we set out to
computationally investigate the phytochemicals from Brucea antidysentrica to identify therapeutic phytochemicals for AML. We performed in silico molecular docking of compounds
against AML receptors IDH2, MCL1, FLT3 and BCL2. Phytochemicals were docked to AML
receptors at the same site where small molecule drugs were bound and their binding affinities were examined. In addition, random compounds from PubChem were docked with AML
targets and their docking score was compared with that of phytochemicals using statistical
analysis. Then, non-covalent interactions between phytochemicals and receptors were
identified and visualized using discovery studio and Protein-Ligand Interaction Profiler web
tool (PLIP). From the statistical analysis, most of the phytochemicals exhibited significantly
lower (p-value � 0.05) binding energies compared with random compounds. Using cutoff
binding energy of less than or equal to one standard deviation from the mean of the phytochemicals’ binding energies for each receptor, 12 phytochemicals showed considerable
binding affinity. Especially, hydnocarpin (-8.9 kcal/mol) and yadanzioside P (-9.4 kcal/mol)
exhibited lower binding energy than approved drugs AMG176 (-8.6 kcal/mol) and gilteritinib
(-9.1 kcal/mol) to receptors MCL1 and FLT3 respectively, indicating their potential to be lead
molecules. In addition, most of the phytochemicals possessed acceptable drug-likeness
and absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties. Based
on the binding affinities as exhibited by the molecular docking studies supported by the
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Combining empirical knowledge and in silico analysis to identify effective natural product-based medicines

statistical analysis, 12 phytochemicals from Brucea antidysentrica (1,11-dimethoxycanthin6-one, 1-methoxycanthin-6-one, 2-methoxycanthin-6-one, beta-carboline-1-propionic acid,
bruceanol A, bruceanol D, bruceanol F, bruceantarin, bruceantin, canthin-6-one, hydnocarpin, and yadanzioside P) can be considered as candidate compounds to prevent and manage AML. However, the phytochemicals should be further studied using in vivo & in vitro
experiments on AML models. Therefore, this study concludes that combination of empirical
knowledge, in silico molecular docking and ADMET profiling is useful to find natural productbased drug candidates. This technique can be applied to other natural products with known
empirical efficacy.

Background
Leukemia is a group of cancers affecting early blood-forming cells. Acute myeloid leukemia
(AML) is an aggressive malignancy of myeloid blood cells, which annually affects more than a
million people globally and results in more than 100,000 deaths [1, 2]. According to American
Cancer Society’s estimates for leukemia in the US for 2020, AML is the deadliest subtype of
leukemia constituting 48% of Leukemia related deaths [3]. The first-line therapy for AML is
chemotherapy [4, 5] and the five-year survival rate is about 28% for all patients and overall survival rate of AML patients across the world is still dismal [6]. The result in older patients who
are unable to receive intensive chemotherapy is very bad with a median survival of only 5 to 10
months [7]. Although there has been some increase in survival for younger patients through
better management of therapy-related toxicities, stem cell transplantation and emergence of
some targeted drugs, AML’s therapy has largely remained unchanged for over four decades
[8] and is still an active topic of research. Recent advances in high-throughput technologies
enabled the elucidation of genetics and pathophysiology leading to detection of recurrent
molecular mutations [9] in AML. FLT3 (Fms-like Tyrosine Kinase 3) is a receptor tyrosine
kinase involved in hematopoiesis and reported to be the most commonly mutated in AML
patients [10, 11]. FLT3 inhibitors such as quizartinib and gilteritinib, are being used in combination with standard chemotherapy to treat AML patients [11]. MCL1 (myeloid cell leukemia1) is a closely related to BCL2 (B-cell lymphoma 2) and both frequently overexpressed in acute
myeloid leukemia and critical for the survival of AML cells and AML stem cells [12, 13]. Venetoclax (ABT-199) is a novel, orally bioavailable small-molecule inhibitor for selective targeting
of BCL2 [14]. AMG 176 is a potent, selective, and orally bioavailable MCL1 inhibitor that
induces a rapid apoptosis in models of hematologic malignancies. The synergistic combination
of AMG 176 and venetoclax demonstrates strong activity in models of AML at tolerated doses,
highlighting the promise of BH3-mimetic combinations in hematologic cancers [15]. IDH1
(Isocitrate dehydrogenase) and IDH2 are two enzymes located in the cytoplasm/peroxysomes
and mitochondria, respectively and point mutations of these enzymes are found in several
malignancies including AML [16]. IDH inhibitors have shown good clinical response in AML
patients and enasidenib and ivosidenib are approved by Food and Drug Administration
(FDA) in 2017 and 2018 for the treatment of adult relapsed or refractory (R/R) AML with
IDH2 and IDH1 mutations, respectively [17].
Natural products have long been a rich source for drug discovery. In four decades of 1981
to 2019, more than 40% (up to 85% with some criteria) of approved small-molecule anticancer
therapeutic agents were naturally inspired [18]. There has been a continuing search of natural
product or natural product inspired molecules for novel anticancer agents. The starting point
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of many of such natural product derived drugs is an empirical knowledge of their therapeutic
effects that passes through generations. Therefore, it would be beneficial to explore traditionally known antileukemic agents as potential sources for treatment and management of AML.
One such potential source is Brucea antidysentrica (B. antidysentrica), a plant used to treat cancer in Ethiopia [19]. Inspired by this traditional and empirical knowledge, studies over the
decades have investigated B. antidysentrica and B. javanica (a closely related plant species used
in Chinese traditional medicine as an anticancer) for their anticancer activities both as crude
extracts and specific compounds [19–22]. Quassinoids from B. antidysentrica such as bruceantin, bruceantinol, bruceantinoside C, brusatol, and bruceantinol have been identified to have
antineoplastic activities in various cancers such as leukemia, breast carcinoma, melanoma,
myeloma, and colon cancer [23–28]. More specifically, spurred by discovery of bruceantin’s
anti-leukemic effect in 1973 by [24], other compounds of B. antidysentrica and B. javanica
such as bruceantinoside A, bruceantinoside B, bruceanol A, bruceanol B, brusatol, and Yadanzioside P were also reported to have antileukemic activities [29–32]. The compounds from B.
antidysentrica have even arrived on Phase II clinical trials for their anticancer activities [28,
33]. To this date, compounds from the B. antidysentrica and B. javanica are being investigated
for their anticancer activities [27, 34].
These previous studies on anticancer effect of B. antidysentrica have been performed by
extraction, identification of the plant’s compounds and testing them on various cancer cell
lines using the long and arduous wet lab processes. As it is known, extraction and testing of
compounds from natural products is a complicated and expensive process [35]. For example,
the whole process of conventional drug discovery from lead identification to drug development is estimated to be 15 years [36] and it may cost around 800 million US dollars [37]. Even
when there is an empirical knowledge of a traditional medicine against specific disease, it is
difficult to identify all compounds from the plants/medicinal materials and test them for their
pharmacological activities. However, numerous compounds are extracted from different
medicinal materials at different times for various purposes. This resulted in buildup of numerous databases of potential therapeutic phytochemicals constituting the medicinal materials.
These compound libraries can be screened for potential drugs using computational methods
such as virtual screening, which is time and cost effective. The traditional medicine inspired
reverse pharmacology is considered faster, economical and safe alternative because their safety
evidence is accumulated from ancestors, the availability could be secured and can be accessed
from mother nature with relatively low cost. Molecular docking is one of the widely used
computational method in which the disease associated target protein is docked with large
libraries of compounds using computer algorithms and their non-covalent binding strength is
characterized by scoring functions [38]. Although molecular docking is a relatively recent in
the field of natural products study, it has been extensively used in structure-based virtual
screening since the early 1980s [39]. It is initiated by identifying disease related targets and
attempts to predict the best interaction mode between target and candidate compounds to
form a stable complex [40]. It is achieved through two steps: first by prediction of ligand conformations as well and its position and orientation in the binding site of the protein (also called
binding poses) and then evaluating the binding affinity of each poses using a scoring function
[41].
Natural products, which are used to treat various kinds of diseases, are usually multi herb
or at least multi-compound concoctions. Although this multi-target polypharmacological
approach might be an important aspect of traditional medicines, it is beneficial to identify specific phytochemical(s) that are actually involved in interacting with the relevant receptors in
order to make targeted treatments, identify their action mechanisms and test their multi-targeting attributes. Such in silico molecular docking studies have been utilized to this end in
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identifying specific natural products’ compounds involved in treating various diseases [42–
46]. In this work, we have demonstrated that empirical knowledge combined with in silico
molecular docking and ADMET profiling is an effective method to identify the anti-leukemic
potential of so-far identified B. antidysentrica phytochemicals. Since AML is morphologically
and genetically heterogenous disease, we approached our work from a multi-target multiligand perspective. There are multiple investigational and approved AML drugs, which target
various receptors. We investigated how well B. antidysentrica compounds can bind to these
various targets and compared the values to the binding energy of the modern drugs, which we
believe can be used as a gold standard for their respective targets. We believe this method can
reveal the compounds, among phytochemicals of the plant, that might be bioactive and have
anticancer activities. To the best of our knowledge, there were no previous efforts to combine
empirical knowledge, in silico molecular docking, ADMET profiling and statistical analysis to
investigate the therapeutic effect of phytochemicals from B. antidysentrica.

Materials and methods
In this research, we used empirical knowledge combined with in silico molecular docking and
DMET profiling to investigate the phytochemicals from traditional medicine plant B. antidysentrica for its potential therapeutic activity on AML. We identified the potential targets for
the B. antidysentrica phytochemicals from the knowledge of the approved small molecules
drugs which are currently being used to treat AML. Although there are multiple approved and
investigational drugs and targets for AML, we selected four of the drugs and targets because
their target-drug interaction complex has been elucidated using 3D crystallography and is publicly available. These drugs are enasidenib, AMG176, gilteritinib and venetoclax with their
corresponding targets IDH2, MCL1, FLT3 and BCL2, respectively. The protein names of the
targets, respectively, are Isocitrate dehydrogenase, Myeloid cell leukemia-1, Fms-like Tyrosine
Kinase 3, and B-cell lymphoma 2. The 3 D Structure Data File (.SDF) file of the drugs are provided as supporting information (S1 File). The drug and target information were identified
from the DrugBank [47], Therapeutic Target Database [48], and literature searches [15, 49,
50]. The 3D structures of the compounds were acquitted from PubChem Database [51],
ChEMBL and/or ZINC database [52] and 3D structure of the targets were acquired from the
Protein Data Bank (PDB) [53]. We selected x-ray crystallographic structures of AML targets
with the small molecule drug complex. Then, in silico molecular docking was employed to predict the interactions between AML targets and compounds based on their poses and binding
free energies, which are expressed as ligand–protein binding forces in kilocalories per mole
(kcal/mol) [54]. We utilized AutoDock vina, which is one of the widely used bioinformatics
tools for docking. The schematic representation of the overall process used in this research is
shown in Fig 1.

Acquisition and preparation of phytochemicals
There has been long history of researches on anticancer activities of compounds from B. antidysentrica. Phytochemicals from this plant were reported to be effective against various cancer
types such as leukemia, breast carcinoma, melanoma, pancreatic adenocarcinoma, and colon
cancer [23–28]. From an extensive literature searches and Ethiopian traditional medicine database (ETM-DB) [55], we compiled compounds of B. antidysentrica (Fig 2A). The phytochemicals 3D SDF were downloaded the PubChem Database, ChEMBL and/or ZINC databases.
The SDF of the phytochemicals were converted to PDB format using open babel [56, 57],
We then used MGL tools to convert the PDB files to PDBQT to prepare PDBQT for AutoDock
Vina, a molecular docking software [58]. Docking algorithms require each atom to have a
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Fig 1. Schematic representation of the various processes used in the study. Briefly, AML targets and modern drugs (small molecule drugs) were
obtained from drug bank, therapeutic target database (TTD) and/or literatures sources. B. antidysentrica phytochemicals were compiled from Ethiopian
traditional medicine database (ETM-DB) and/or literatures. Then, the modern drugs, phytochemicals and random compounds (obtained from
PubChem) were docked with AML targets. Binding energies of small molecule drugs and phytochemicals were evaluated against that of random
compounds with statistical test. Finally, the candidate therapeutic phytochemicals were selected based on the statistical analysis and cutoff binding
energies. In addition, the candidate compounds were further evaluated for drug-likeness, physicochemical and ADMET properties.
https://doi.org/10.1371/journal.pone.0270050.g001

charge and an atom type that describes its properties. Therefore, both ligands and targets
should be prepared properly to include these values. For each ligand, ADT automatically adds
gasteiger charges, non-polar hydrogen atoms and detects rotatable bonds [59].

Acquisition and preparation of molecular drug targets
Small molecule modern drugs and AML therapeutic targets were retrieved from Drug Bank
database [60], Therapeutic Target Database (TTD) [61] and literature searches. The AML chemotherapeutic small molecule drugs used in this study were enasidenib, AMG176, gilteritinib
and venetoclax with their target proteins: Isocitrate dehydrogenase (IDH2), Induced myeloid
leukemia cell differentiation protein (MCL1), FLT3 and BCL2 respectively (Fig 2B). The
crystallographic structures of the target protein and small molecule drug complexes were
obtained from the Protein Data Bank (PDB) [62] with PDB IDs 5I96, 6O0F, 6JQR and 6O0K
respectively.
The crystallographic structures PDB file contains protein, ligand, water oxygen atoms.
Also, crystal structures normally lack polar hydrogen atoms which are required for appropriate
treatment of electrostatics during docking [59]. For each protein, all the water molecules were
removed, polar hydrogens and Kollman charges were added and the PDB files were converted
to PDBQT to prepare for docking using ADT [58, 59].
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Fig 2. 2D structures of the investigated compounds in this study. (A) Selected B. antidysentrica phytochemicals and (B) Small molecule drugs.
https://doi.org/10.1371/journal.pone.0270050.g002

Molecular docking study
The 3D structure of the targets were small molecule drug-target complexes. We removed the
small molecule drugs from the drug-target complexes using PyMol [63]. The positions of the
small molecule drugs were considered as binding sites of the targets. The small molecule drugs
were then re-docked to their corresponding targets and their binding scores were compared
with that phytochemicals and random compounds. The binding energies of the small molecule
drugs to their corresponding targets were much lower than the random compounds and most
of the phytochemicals binding energy (see Results) indicating the rationality of our binding
site identification method. Phytochemicals from B. antidysentrica and random compounds
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from PubChem were docked to AML receptors keeping all the docking parameters similar to
the parameters of the small molecule drugs.
AutoDock Vina was used to do molecular docking in this work. During the docking procedure, both the protein and ligands were considered as rigid to minimize complexity that may
arise from the large size of proteins and their multiple degrees of freedom [41]. All ligands
(phytochemicals, small molecule drugs, and random compounds) were docked to individual
receptors with grid coordinates and grid boxes of certain sizes for each receptor. The dimension of the grid box was set to a default value of 30 and the grid box centers were defined as the
center of small molecule drug bound to the AML targets. The receptors and the grid center (x,
y, z) used were as follows: 5I96 (-1.396, 15.123, -28.458), 6O0F (-14.521, 8.041, -18.915), 6JQR
(-28.036, -10.299, -28.981), and 6O0K (-15.258, 2.212, -9.458) respectively. The exhaustiveness
parameter that controls the extent of the search was set to 32. For each ligand, the pose with
lowest energy of binding was retrieved and aligned with receptor structure for further analysis.
Eventually, compounds with computed docking energy of less than or equal to cutoff binding energy were selected as the candidate therapeutic phytochemicals. The cutoff binding
energy for each AML target was set to the mean of the binding energies of all the phytochemicals minus their standard deviation (mean—SD in kcal/mol). The docking scores and the 2D
and 3D pose views were generated for further analysis.

Statistical analysis
In order to show that empirical knowledge combined with in silico molecular docking and
ADMET profiling is one of the effective methods to identify natural product-based medicines
and as an approach to validate our results, around 100 compounds from PubChem were
docked with AML targets keeping all the docking parameters similar to for small molecule
drugs and phytochemicals. Then a one-sample one-sided t-test was applied to measure the statistical significance (P � 0.05) of the binding affinities of the small molecule drugs and B. antidysentrica phytochemicals compared to that of random compounds. We used python scripts
to download the random compounds and to automate statistical analysis as well as to plot the
docking scores for the compounds (small molecule drugs, phytochemicals, and random compounds) for each AML targets.

Post docking analysis
The interactions between the compounds and the drug targets were examined in both 3D and
2D orientations. The docking poses were selected based on cutoff binding energies, which was
set to less than or equal to one standard deviation from the mean of the phytochemicals’ binding energies for each receptor. Post docking analyses were carried out using PyMOL [63] and
BIOVIA Discovery Studio [64]. PyMOL was used to visualize the docked protein and ligand
complex binding pose and to convert the PDBQT format of AutoDock Vina output to PDB
format. Then, the PDB format of the docked target protein and ligand complex were further
visualized and analyzed using BIOVIA Discovery Studio, which showed the locations of binding sites and nature of interactions between the target protein and the docked ligand. Furthermore, non-covalently interacting residues of the target protein with the compounds were
predicted using Protein-Ligand Interaction Profiler (PLIP) webserver [65].

Drug-likeness properties, ADMET properties, and interactions with P-gp
and CYP isoenzymes of the compounds
Evaluation of drug-likeness and ADMET properties, estimation for a compound to be substrate of P-gp or inhibitor of the most important CYP isoenzymes of the compounds were
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calculated using a website SwissADME [66], which is a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Toxicity of the
phytochemicals and small molecule drugs were predicted using web interface of ProTox-II,
which is user friendly and can predict potential toxicities associated with a chemical structure
from user inputs of the name of the compound or the SMILES (Simplified Molecular-Input
Line-Entry System) string of the compound [67]. In this work, we evaluated the acute toxicity
of the compounds which are based on chemical similarities between compounds with known
toxic effects and the presence of toxic fragments [68].

Computation environment
All the locally installable software programs or scripts were implemented in an automatic fashion using Windows Command Prompt Commands and Python 3.8 on windows 10. All simulations were performed on a Windows 10 computer (Intel(R) Core (TM) i5-4690 CPU @
3.50GHz, 3501 Mhz, 4 Core(s), and 4 Logical Processor(s)). The configuration of the RAM: 4
slots, 3 of them each having 8 GB RAM and 1 slot 4 GB RAM giving a combined 28 GB, DDR3
and speed of 1600MHz.

Results and discussion
Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid blood cells, which
annually affects more than a million people globally and results in more than 100,000 deaths
[1, 2]. The major intervention is stem cell transplantation which is unbearable for elderly and
severe comorbid patients thereby necessitating for complementary and alternative therapies.
Recent advances in high-throughput technologies enabled the elucidation of genetics and
pathophysiology leading to identification therapeutic targets [9]. To this end, IDH2, MCL1,
FLT3 and BCL2 are identified as drug targets for treatment of AML patients [10, 12, 13, 16].
In this research, we used information on the identified drug targets and small molecule
drugs for treatment of AML to evaluate the therapeutic potential of phytochemicals from B.
antidysentrica targeting AML receptors. The X-ray crystallographic structures of the AML
receptors (IDH2, MCL1, FLT3 and BCL2) used in this research was downloaded from the
PDB with PDB IDs 5I96, 6O0F, 6JQR and 6O0K respectively. Hence, we proposed to identify
potential inhibitors of AML therapeutic target proteins by combining traditional empirical
knowledge and in silico molecular docking. AutoDock Vina was reported as the best software
to implement docking giving rise to poses that bind best deep inside the 5 Å of the binding
pocket [69]. The docking process returned top ten ranked docking poses for each compound.
In each case, we selected the topmost docking poses with Root Mean Square Deviation
(RMSD) values of 0 Å.
From the 38 phytochemicals identified from B. antidysentrica, 30 of them have 3D structures in PubChem, ChEMBL and/or ZINC databases. The 3 D SDF file of these phytochemicals are provided as supporting information (S2 File). The remaining 8 compounds either lack
3D structures or their conformer generation were rejected. 3D representations for bruceanic
acids B, C, and D are not available. For bruceanic acid A, yadanziosides G and M, bruceantinosides B and C, conformer generation were disallowed because of too many undefined stereo
centers. In silico molecular docking was performed for phytochemicals with 3D structures.
The statistical analysis for testing the significance of the docking scores of B. antidysentrica phytochemicals compared to random compounds showed that most of the phytochemicals have significant lower binding affinities (p-value � 0.05). The 3 D SDF file of random
compounds used are provided as supporting information (S3 File). In addition to 3D
structures, we provided 2D structures of all the investigated compounds as supporting
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information for reference (S4 and S5 Files). The binding energies of the of small molecule
drugs, phytochemicals and random compounds are visualized in Fig 3A and 3B as a scatter
plot indicating that the small molecule drugs and phytochemicals have lower binding energies than random compounds. The docking scores of the all investigated phytochemicals and
the p-values are available in supporting information (S6 File). This result is a step toward validating the traditionally claimed empirical knowledge of the therapeutic potential of B. antidysentrica and its compounds against AML. Furthermore, based on the chosen cutoff energy
(mean-SD), 12 phytochemicals showed substantial binding affinity compared to the standard
approved drugs. Especially, hydnocarpin and yadanzioside P exhibited better binding affinity compared to the approved drugs which targets MCL1 and FLT3 receptors, respectively.
Hydnocarpin has lower binding energy (-8.9 kcal/mol) with MCL1 receptor compared to the
small molecule drug AMG176 (-8.6 kcal/mol) on the same receptor. Similarly, yadanzioside
P has lower binding energy (-9.4 kcal/mol) to FLT3 receptor compared with the small molecule modern drug gilteritinib (-9.1 kcal/mol). Furthermore, phytochemicals bruceanol D
(-8.9 kcal/mol), bruceantin (-8.8 kcal/mol), hydnocarpin (-8.7 kcal/mol) also have closely
similar binding affinities to FLT3 receptor with approved drug gilteritinib. These results
demonstrated that numerous phytochemicals from B. antidysentrica has considerable binding affinities with AML targets signifying their therapeutic potential for treatment and management of AML.
The nature of interaction and interacting amino acid residues of the best docking poses in
the binding sites of the receptors with selected phytochemicals was predicted using ProteinLigand Interaction Profiler (PLIP) automated web tool and the results are summarized in in
Table 1. The 3D and 2D view of the interactions between the selected B. antidysentrica phytochemicals and the AML receptors are shown in Figs 4–7.
Most of the interactions between the target proteins and ligands (small molecule drugs
and phytochemicals) (Table 1) are hydrophobic interactions. Analysis of marketed drugs
revealed that the average number of hydrophobic atoms is 16 [70], indicating the importance
of hydrophobic interactions in drug designing. Hydrophobic interactions increase the binding affinity between target-drug interfaces and enhance biological activity of complex molecules as well as help in stabilizing the biochemical environments of target-drug complexes
[71]. Hydrophobic interactions are dominant for all receptors with both small molecule standard drugs and phytochemicals. However, for the receptor FLT3, there are also considerable
formations of hydrogen bond interactions compared with the other receptors. Previous
works done to understand the drug efficacy concluded that the binding affinity of the targetreceptor molecules were increased by optimizing the hydrophobic interactions by captivating hydrogen bonding [71].
2-methoxycanthin-6-one showed interactions with receptor IDH2 forming hydrophobic
interactions with Trp164B, Val279B, and Ile319 residues, with low binding energy of -11.9
kcal/mol next to the co-crystalized ligand pose with binding affinity score of −14.88 kcal/mol.
Similarly, canthin-6-one, 1-methoxycanthin-6-one, beta-carboline-1-propionic acid, bruceanol A, 1,11-dimethoxycanthin-6-one showed consecutive binding affinity with mainly hydrophobic interaction indicating good binding mode with important interactions. Similar
scenarios could be drawn for the remaining receptors. It is interesting to note that hydnocarpin showed more hydrophobic interactions and hydrogen bonds with receptor MCL1 and the
binding energy is also lower compared to standard drug AMG176. This indicates that hydnocarpin can be considered a lead compound targeting MCL1 receptor. Similarly, Yadanzioside
P showed more hydrophobic interactions and hydrogen bonds with lower binding energy to
receptor FLT3 compared to standard drug gilteritinib, signifying its potential as a lead compound targeting FLT3.
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Fig 3. Scatter plots of the docking scores of compound-target interactions for each AML therapeutic targets. (A)
compound—target docking score visualization for each AML targets, (B) compound—target docking scores combined
for all the four AML targets.
https://doi.org/10.1371/journal.pone.0270050.g003
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Table 1. Binding affinity energies, nature of interaction and interacting amino acid residues between the compounds (small molecule drug and phytochemicals)
and AML receptors.
Small molecule drug and
phytochemicals

Target (PDB Docking score (kcal/ p-value
ID)
mol)

Hydrophobic interaction

Hydrogen bonds

Enasidenib

IDH2 (5I96)

-14.8

1.21E66

Leu160B, Trp164, Ile290, Val297, Val297B, Leu298, NA
Trp306B, Val315

2-methoxycanthin-6-one

IDH2 (5I96)

-11.9

9.44E43

Trp164B, Val279B, Ile319

NA

Canthin-6-one

IDH2 (5I96)

-11.5

2.16E38

Leu298, Ile319

NA

1-methoxycanthin-6-one

IDH2 (5I96)

-11.1

1.09E33

Leu160, Leu298, Trp306B

Gln316

Beta-carboline-1-propionic acid

IDH2 (5I96)

-10.9

1.87E32

Trp164B, Val279B, Ile319

NA

Bruceanol A

IDH2 (5I96)

-10.7

3.37E31

Val147, Arg149, Arg172

Arg149, Arg172, Asp314

1,11-dimethoxycanthin-6-one

IDH2 (5I96)

-11.0

1.28E28

Leu160, Trp164, Trp164B, Val297B

NA

Hydnocarpin

IDH2 (5I96)

-10.1

2.15E20

NA

Arg149B, Lys299

AMG176

MCL1(6O6F)

-8.6

2.91E13

Phe228, Met231, Val253, Thr266

NA

Hydnocarpin

MCL1(6O6F)

-8.9

1.85E18

Met250, Val253, Phe254, Leu267, Phe270, His224B

NA

Beta-carboline-1-propionic acid

MCL1(6O6F)

-8.5

1.43E11

Leu246, Phe270, Gly271, Leu290

Arg263

2-methoxycanthin-6-one

MCL1(6O6F)

-8.4

6.34E10

Leu235, Leu246, Phe270, Leu290

NA

Bruceanol F

MCL1(6O6F

-8.4

1.73E05

Met231, Phe270

His 224B, His224B,
Arg263

Gilteritinib

FLT3 (6JQR)

-9.1

1.23E16

Val675, Phe830

Leu616

Yadanzioside P

FLT3 (6JQR)

-9.4

2.53E21

Leu616, Ala642, Tyr693, Asp698, Leu818, Phe830,
Tyr842

Gln575, Leu616, Arg815

Bruceanol D

FLT3 (6JQR)

-8.9

1.62E13

Leu616, Gly617, Gly619, Val624, Leu818, Phe830

Val624, Asp698, Phe830,
Tyr842

Bruceantin

FLT3 (6JQR)

-8.8

5.54E12

Leu616, Gly617, Gly619, Val624, Leu818, Phe830

Asp698, Phe830, Tyr842

Hydnocarpin

FLT3 (6JQR)

-8.7

1.75E10

Val675, Phe691, Arg815, Leu818, Cys828, Phe830

Arg815

Venetoclax

BCL2 (6O0K)

2.01E52

Phe104, Tyr108, Val133, Leu137, Tyr202

NA

Bruceantarin

BCL2 (6O0K)

-8.6

2.24E17

Phe104, Met115, Leu137, Lew137, Ala149, Phe153

Asp140

Hydnocarpin

BCL2 (6O0K)

-8.4

8.84E14

Phe104, Arg146, Val148, Ala149

Arg146

Bruceanol A

BCL2 (6O0K)

-8.3

5.16E12

Phe104, Met115, Val133, Glu152, Val156

NA

Bruceantin

BCL2 (6O0K)

-8.1

1.22E08

Asp111, Met115, Leu137, Ala149, Phe153, Val156

Asp140

-11

https://doi.org/10.1371/journal.pone.0270050.t001

In silico analysis should be complemented with other pharmacological profiling [72]. Compounds such as those that contain reactive groups, insoluble compounds, compounds that are
too large/less extendable, or highly flexible compounds [66] should be screened.
Drug-likeness is related to molecular properties affecting pharmacodynamics and pharmacokinetics of the molecules. These molecular properties are related to some basic structural or
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Fig 4. Molecular docking analysis of enasidenib and selected B. antidysentrica phytochemicals against IDH2 AML
receptor. (1) 3D pose views of interaction of compounds with AML receptor IDH2. (2) 2D pose views of interaction of
compounds with AML receptor IDH2.
https://doi.org/10.1371/journal.pone.0270050.g004
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Fig 5. Molecular docking analysis of AMG176 and selected B. antidysentrica phytochemicals against MCL1 AML receptor. (1) 3D pose views of
interaction of compounds with AML receptor MCL1. (2) 2D pose views of interaction of compounds with AML receptor MCL1.
https://doi.org/10.1371/journal.pone.0270050.g005

physicochemical properties such as log p (partition coefficient), molecular weight (MW),
Topological polar surface area (TPSA), hydrogen bond acceptors and donors count in a molecule. There are several sets of criteria to select ligands for a potential drug. Most notably,
Lipinski [73] identified common properties that are frequently observed in approved compounds. They present a “rule of 5” for drug-like molecules (less than 5 hydrogen bond donors,
less than 10 hydrogen bond acceptors, less than 500 dalton molecular weight, and less than 5
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Fig 6. Molecular docking analysis of gilteritinib and selected B. antidysentrica phytochemicals against FLT3 AML receptor. (1) 3D pose views of interaction of
compounds with AML receptor FLT3. (2) 2D pose views of interaction of compounds with AML receptor FLT3.
https://doi.org/10.1371/journal.pone.0270050.g006
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Fig 7. Molecular docking analysis of venetoclax and selected B. antidysentrica phytochemicals against BCL2 AML receptor. (1) 3D pose views of
interaction of compounds with AML receptor FLT3. (2) 2D pose views of interaction of compounds with AML receptor BCL2.
https://doi.org/10.1371/journal.pone.0270050.g007

log p (partition coefficient between organic and aqueous phases). In addition, Veber’s rule [74]
suggested that compounds which meet only the two criteria of 10 or fewer rotatable bonds and
polar surface area equal to or less than 140 Å2 will have a high probability of good oral bioavailability in the rat. However, many of the most successful drugs do not fit these guidelines, and
care should be taken in application of these guidelines [72].
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Table 2. Lipinski’s rule of five and Veber’s rule for drug-likeness analysis of selected phytochemicals and small molecule drugs.
Compounds

Molecular
weight (g/mol)

Lipophilicity
(log p)

Hydrogen bond
donors

Hydrogen bond
acceptors

280.28

2.12

0

4

TPSA ROTB Number of Lipinski’s Number of Veber’s
rule violations
rule violations

Phytochemicals
1,11-dimethoxycanthin6-one

107.59

2

0

0

1-methoxycanthin-6-one

250.25

2.39

0

3

43.6

1

0

0

2-methoxycanthin-6-one

250.25

2.73

0

3

43.6

1

0

0

Beta-carboline-1-propionic
acid

240.26

2.11

2

3

65.98

3

0

0
1

Bruceanol A

542.53

0.7

3

11

165.89

5

2

Bruceanol D

548.58

1.25

3

11

165.89

6

2

1

Bruceanol F

548.58

2.28

3

11

165.89

6

2

1

Bruceantarin

542.53

1.11

3

11

165.89

5

2

1

Bruceantin

548.58

1.66

3

11

165.89

6

2

1

Canthin-6-one

220.23

2.42

0

2

34.37

0

0

0

Hydnocarpin

464.42

3.73

4

9

138.82

4

1

0

Yadanzioside P

710.72

-0.14

6

16

245.04

9

2

1

Small molecule drugs
Enasidenib

473.4

3.5

3

14

109

8

2

0

AMG176

613.2

6.8

1

6

93.3

1

2

0

Gilteritinib

552.7

3.5

3

10

121

9

1

0

Venetoclax

868.4

8.2

3

11

183

14

3

2

TPSA: topological polar surface area, ROTB: number of rotatable bonds
https://doi.org/10.1371/journal.pone.0270050.t002

Most of the investigated B. antidysentrica phytochemicals obeys most of the Lipinski’s and
Veber’s rule similar to that of approved small molecule drugs as shown in Table 2. We used
compounds with two or more Rule of 5 violations being used in drug development by medicinal chemists and industries [75] as a reference for drug-likeness evaluation of the phytochemicals in this work. Especially over the past two decades, the increasing significance of drugs not
conforming to this rule is illustrated by the increase in molecular mass of approved oral drugs,
compelling evidence to contradict the suggestion that molecular weight is a “drug-like” property [76, 77], Since natural products contain enormous scaffold diversity and structural complexity and typically possesses high molecular weights, a larger number of sp3 carbon atoms
and oxygen atoms but fewer nitrogen and halogen atoms, higher numbers of H-bond acceptors and donors, lower calculated octanol–water partition coefficients (cLog P values, indicating higher hydrophilicity) and greater molecular rigidity compared with synthetic compound
libraries, they are a main source of oral drugs ‘beyond Lipinski’s rule of five’ [76, 78], In addition, most of the compounds contain acceptable molecular weight and convenient TPSA values as shown in Table 3. In order to investigate majority of compounds for drug development
purpose, compound with molecular weight of greater than 500 dalton and less than 3000 dalton are being used [78]. Therefore, the selected B. antidysentrica phytochemicals possesses sufficient drug-likeness and physicochemical properties suggesting their potential as therapeutic
drug as shown in Tables 2 and 3.
The predicted log p value and Abbott bioavailability score (greater than zero) revealed that
the compounds have a substantial bioavailability and cross the cell membrane efficiently [78].
Gastrointestinal absorption (GIA) and blood–brain barrier (BBB) permeation of the phytochemicals are also comparable to that of standard small molecule approved drugs (Table 3).
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Table 3. Calculated physicochemical properties and toxicity class of selected B. antidysentrica phytochemicals and small molecule drugs.
Compounds

Molecular weight (g/
mol)

log p Water solubility Silicos-IT
class

GI
absorption

BBB
permeant

Abbott bioavailability
score

Toxicity
class

Phytochemicals
1,11-dimethoxycanthin-6-one

280.28

2.12 Moderately soluble

High

No

0.55

4

1-methoxycanthin-6-one

250.25

2.39 Moderately soluble

High

yes

0.55

4

2-methoxycanthin-6-one

250.25

2.73 Moderately soluble

High

yes

0.55

3

Beta-carboline-1-propionic
acid

240.26

2.11 Moderately soluble

High

yes

0.85

3

Bruceanol A

542.53

0.7

Soluble

Low

No

0.17

2

Bruceanol D

548.58

1.25 Soluble

Low

No

0.17

2

Bruceanol F

548.58

2.28 Soluble

Low

No

0.17

2

Bruceantarin

542.53

1.11 Soluble

Low

No

0.17

4

Bruceantin

548.58

1.66 Soluble

Low

No

0.17

2

Canthin-6-one

220.23

2.42 Moderately soluble

High

yes

0.55

4

Hydnocarpin

464.42

Yadanzioside P

710.72

3.73 Poorly soluble
-0.14 Soluble

Low

No

0.55

5

Low

No

0.17

2

Small molecule drugs
Enasidenib

473.4

3.5

Poorly soluble

Low

No

0.55

4

AMG176

613.2

6.8

Poorly soluble

Low

No

0.55

4

Gilteritinib

552.7

3.5

Poorly soluble

High

No

0.17

4

Venetoclax

868.4

8.2

Insoluble

Low

No

0.17

4

Toxicity class: Class 1: fatal if swallowed (LD50 � 5); Class 2: fatal if swallowed (5 < LD50 � 50); Class 3: toxic if swallowed (50 < LD50 � 300); Class 4: harmful if
swallowed; (300 < LD50 � 2000); Class 5: may be harmful if swallowed (2000 < LD50 � 5000); Class 6: non-toxic (LD50 > 5000)
https://doi.org/10.1371/journal.pone.0270050.t003

The phytochemicals exhibited acceptable gastrointestinal absorption which is an important
property of a drug that is intended for mass treatment. In addition, phytochemicals 1-methoxycanthin-6-one, 2-methoxycanthin-6-one, beta-carboline-1-propionic acid and Canthin6-one can cross the blood-brain barrier. The remaining compounds do not cross blood-brain
barrier similar to that of small molecule approved drugs. The Brain Or Intestine EstimateD
(BOILED-Egg) model prediction of GIA and BBB permeation for small molecule drugs and B.
antidysentrica phytochemicals is presented in Fig 8. The compounds 2-methoxycanthin-6-one

Fig 8. BOILED-Egg model of small molecule standard drugs and selected B. antidysentrica phytochemicals.
https://doi.org/10.1371/journal.pone.0270050.g008
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Table 4. Interaction of selected B. antidysentrica phytochemicals and small molecule modern drugs with P-glycoprotein and cytochrome P450 isoenzymes.
Phytochemicals

Pgp substrate

CYP1A2 inhibitor

CYP2C19 inhibitor

CYP2C9 inhibitor

CYP2D6 inhibitor

CYP3A4 inhibitor

Phytochemicals
1,11-dimethoxycanthin-6-one

No

Yes

No

Yes

Yes

Yes

1-methoxycanthin-6-one

No

Yes

No

No

No

Yes

2-methoxycanthin-6-one

No

Yes

No

No

No

No

Beta-carboline-1-propionic acid

No

Yes

No

No

No

No

Bruceanol A

Yes

No

No

No

No

No

Bruceanol D

Yes

No

No

No

No

No

Bruceanol F

Yes

No

No

No

No

No

Bruceantarin

Yes

No

No

No

No

No

Bruceantin

Yes

No

No

No

No

No

Canthin-6-one

No

Yes

No

No

No

No

Hydnocarpin

No

No

No

Yes

No

Yes

Yadanzioside P

Yes

No

No

No

No

No

Small molecule drugs
Enasidenib

No

Yes

No

Yes

Yes

Yes

AMG176

Yes

No

No

No

No

No

Gilteritinib

No

No

Yes

No

No

No

Venetoclax

Yes

No

No

No

No

No

https://doi.org/10.1371/journal.pone.0270050.t004

from phytochemicals and Venetoclax from the small molecule drugs were out of range of the
BOILED-Egg model diagram.
Toxicity class of the phytochemicals range from class 2 (fatal) to 5 (may be harmful) and
that of small molecule drugs are class 4 (harmful) which indicates that the phytochemicals
have comparable to the acute toxicity to approved modern small molecule drugs.
Permeability glycoprotein (P-gp) is an ATP-binding cassette (ABC) membrane transporter,
which limits cellular uptake, distribution, excretion and toxicity of compounds by acting as a
unidirectional efflux pump to extrude its substrate from inside to outside of cells thereby
obstructing cell internalization of chemotherapeutic agents [79, 80], From Table 4, it can be
seen that 50% of the phytochemicals and small molecule drugs are not substrates of P-glycoprotein, demonstrating their desirable properties as potential chemotherapeutic agents. On the
other hand, the remaining half of the phytochemicals and small molecule drugs are substrates
of P-glycoprotein, suggesting that various strategies should be used to tackle this curb in the
field of drug delivery and targeting.
Cytochrome P450s (CYPs) represent a large class of heme-containing enzymes that catalyze
the metabolism of multitudes of substrates including chemotherapeutic agents. Therefore,
strategies to inhibit the enzymes are one approaches for the treatment and prevention of cancer [81]. The phytochemicals 1,11-dimethoxycanthin-6-one, 1-methoxycanthin-6-one,
2-methoxycanthin-6-one, beta-carboline-1-propionic acid, canthin-6-one inhibits CYP1A2
enzyme activity and that these inhibitory effects may contribute towards the cancer preventive
action of the compounds. Similarly, phytochemicals 1,11-dimethoxycanthin-6-one, 1-methoxycanthin-6-one and hydnocarpin are inhibitors of CYP3A4 indicating their potential as chemotherapeutic agents.

Conclusions
When a specific target gene or protein that is differentially expressed in cancer is found, the
search for small molecules targeted therapies is usually performed using high throughput
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screening. Although this is the gold standard, it is a time consuming and expensive process.
Therefore, computational drug discoveries have been extensively employed in assisting the
process of finding lead compounds in such targeted therapies. In addition, starting this search
from the empirical traditional knowledge of natural products in treating some ailments can
therefore help in saving cost and time. Combining the computational approach with the
empirical knowledge of natural products can even make the process faster and cheaper. Therefore, in this work, starting from empirical knowledge and using computational methods, we
set out to find the compounds of B. antidysentrica involved in potentially treating AML. Based
on the binding affinities as exhibited by the molecular docking studies and supported by the
statistical analysis, the current study concludes that the 12 phytochemicals from B. antidysentrica can be considered as possible agents against IDH2, MCL1, FLT3 and BCL2 receptors.
Hence, this study has partially recognized the traditionally claimed anti-leukemic activity
of the plant. In addition, most of the phytochemicals were found to have acceptable druglikeness and ADMET properties showing their potential as drug candidates. Similar in silico
approaches can be applied the study of other traditional medicinal materials to identify new
potential therapeutic compounds.
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